Sentences with phrase «non-small cell lung cancer»

The plaintiff claimed that the defendant misread the 1/15/10 chest x-ray resulting in a 3 year delay in diagnosis of non-small cell lung cancer.

It is currently approved for the treatment of a number of different cancers including metastatic colon cancer, and non-small cell lung cancer.

This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first - line treatment of patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

It's unbelievable story how she was left to die with Stage IV, non-small cell lung cancer.

Mazurak and her colleagues asked 16 patients with non-small cell lung cancer to take a 2.2 - gram supplement of eicosapentaenoic acid, a compound in fish oil, once a day during their 10 - week chemotherapy treatments.

[4] Cell studies have shown that vitamin C is toxic to prostate cancer, [5] non-small cell lung cancer, [6] and colon cancer cells, [7] while animal studies have shown that it may have some efficacy in the treatment of melanoma [8] and mesothelioma, the latter being notoriously difficult to treat.

The FDA approved two anti-PD-1 antibodies (nivolumab / Bristol - Myers Squibb and pembrolizumab / Merck & Co.) for metastatic melanoma in 2014, and it extended approval to metastatic squamous non-small cell lung cancer earlier this year.

These include imatinib, sold under the brand name Gleevec for chronic myeloid leukemia; gefitinib, sold as Iressa for metastatic non-small cell lung cancer; and sunitinib, marketed as Sutent, for renal cell cancer and gastrointestinal stromal tumors.

For patients with non-small cell lung cancer with brain metastases, treatment with whole brain radiotherapy may not offer much benefit.

YEATS4 Is a Novel Oncogene Amplified in Non-Small Cell Lung Cancer That Regulates the p53 Pathway.

If clinical trials of anti-PD-1 continue to show promising results, cancer patients may soon have access to another powerful immunotherapy for the treatment of numerous cancers, including melanoma, non-small cell lung cancer, and other solid tumors.

45) * Coe BP, * Lockwood WW, Girard L, Chari R, MacAulay C, Lam S, Gazdar AF, Minna JD, Lam WL (2006) Differential regulation of cell cycle pathways in small cell and non-small cell lung cancer.

Paclitaxel by either 1 - hour or 24 - hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.

Neutrophil - to - Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor

In March, the U.S. Food and Drug Administration approved nivolumab for patients with advanced (metastatic) squamous non-small cell lung cancer.

The once - daily drug targets advanced non-small cell lung cancer, the most common type of lung cancer.

42) Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Merck's cancer drug Keytruda got the nod of U.S. regulators as a first - line drug for treating metastatic non-small cell lung cancer.

Weekly irinotecan and concurrent radiation therapy for stage III unresectable non-small cell lung cancer.

Combination of Advanced Lung Cancer Inflammation Index and C - Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patients.

Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patients.

Saturday, Oct. 21, 9:15 - 9:30 a.m., Room 220B, South Building Platform Presentation: Epigenetic modifications of innate immunity genes impact early - stage non-small cell lung cancer survival: An integrative analysis of epigenome and transcriptome in Caucasian population R. Zhang, Harvard T.H. Chan School of Public Health, et al

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).

8) Shah P, Lockwood WW, Saurabh K, Kurlawala M, Shannon S, Waigel S, Zacharias W, Beverley LJ (2014) Ubiquilin1 represses migration and epithelial to mesenchymal transition of human non-small cell lung cancer cells.

Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A phase II multicenter study.

This on - demand webinar offers advice from three experts on immunotherapy in non-small cell lung cancer.

Pembrolizumab, which has already been shown safe and effective as monotherapy for advanced, non-squamous non-small cell lung cancer (NSCLC), might also be an effective component in combination therapy for the disease.

Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for approximately 90 % of all lung cancer cases.

Autocrine / paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase - 2 and CD44 in cyclooxygenase -2-dependent invasion.

Cyclooxygenase 2 - dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.

Cyclooxygenase -2-dependent expression of angiogenic CXC chemokines ENA - 78 / CXC Ligand (CXCL) 5 and interleukin - 8 / CXCL8 in human non-small cell lung cancer.

Life table modelling on the basis of these data estimated 33 % five year survival in 65 year old patients with early stage non-small cell lung cancer who continued to smoke compared with 70 % in those who quit smoking.

A total of 13 Dream Team clinical trials are active right now, for patients with bladder cancer, kidney cancer, prostate cancer, triple - negative breast cancer, gastric cancer, pancreatic cancer, small cell and non-small cell lung cancer, sarcoma, and melanoma, and seven more trials are planned.

The Sandpiper Trial is evaluating the proposed combination therapy in patients with non-small cell lung cancer (NSCLC) no longer responsive to chemotherapy.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

For patients with early - stage non-small cell lung cancer (NSCLC), the only recommended treatment option is surgery.

Four studies reported estimates of the association between continued smoking and all cause mortality, one study reported the association with occurrence of a second primary tumour, and one study with recurrence in non-small cell lung cancer (fig 2 ⇓).

Non-small cell lung cancer accounts for around 85 per cent of all lung cancer cases.

Along the same lines, in non-small cell lung cancer (NSCLC), acquired resistance to Gefitinib / Erlotinib kinase inhibitors has also been associated with a secondary mutation of the gatekeeper Thr790 residue of the epidermal growth factor receptor (EGFR).

This part will enroll subjects with certain types of endometrial cancer, melanoma, non-small cell lung cancer, and renal (kidney) cancer.

Shapiro GI, Koestner DA, Matranga CB, et al: Flavopiridol induces cell cycle arrest and p53 - independent apoptosis in non-small cell lung cancer cell lines.

Joint evidence - based guideline to improve care for patients with non-small cell lung cancer (NSCLC).

Assuming that the findings of the review reflected a causal relation between smoking cessation and risk of all cause mortality, we further investigated the data by constructing life tables for a hypothetical group of 100 patients aged 65 years with early stage lung cancer to estimate how many deaths would be prevented by smoking cessation within the non-small cell lung cancer and small cell lung cancer populations during five years.

The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.

In project on BRAF - mutant melanoma and EGFR - mutant non-small cell lung cancer, we conceived a novel drug sensitivity metric, the DIP rate, that makes it possible to incorporate drug - induced proliferation rates in predictive models of response.

No study contained data on the effect of quitting smoking on cancer specific mortality or on development of a second primary tumour in non-small cell lung cancer.

Life tables were used to model five year survival for early stage non-small cell lung cancer and limited stage small cell lung cancer, using death rates for continuing smokers and quitters obtained from this review.

Among the most exciting findings of these studies is that a significant proportion of patients with non-small cell lung cancer (NSCLC) respond dramatically to anti-PD-1 treatment.

In both early stage non-small cell lung cancer and limited stage small cell lung cancer, we found evidence of a significant association between continued smoking and recurrence of the primary tumour; in limited stage small cell lung cancer, we found also evidence of a substantial elevation in the incidence of a second primary tumour.

The life table analysis was based on a notional cohort of 65 year old smokers diagnosed with early stage non-small cell lung cancer or limited stage small cell lung cancer.